In VivoThe new drugs that hit the market in 2024 included medicines to address an array of high unmet medical need, but the US Food and Drug Administration approval of several drugs for liver disease put a s
In VivoGlen Clova Scientific is a biotech startup taking a novel approach to treating chronic conditions, with a focus on debilitating skin and immune disorders. Founded in 2022 by dermatologist John Foerste
ScripA month after shelving its previous lead drug candidate, izokibep, Acelyrin said on 6 January that it is moving lonigutamab into Phase III in thyroid eye disease with a revised dosing regimen from Pha
ScripAs multiple companies have – with varying degrees of success – sought to develop next-generation drugs for treating overweight and obesity, Metsera has shown that it is feasible to administer its GLP-